Jupiter Neurosciences (JUNS) announced it has entered into an agreement with Catalent Pharma Solutions for the production of JOTROL softgel capsules to support Jupiter’s upcoming Phase 2a clinical trial in Parkinson’s disease. Under the terms of the agreement, Catalent will manufacture clinical batches of JOTROL, Jupiter’s proprietary resveratrol-based therapeutic, using an optimized softgel formulation. The production will include both active and placebo batches for the Parkinson’s study. This manufacturing initiative will be conducted under current Good Manufacturing Practices to meet regulatory and clinical standards.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JUNS:
- Jupiter Neurosciences partners with Zina Biopharmaceuticals to advance Phase 2a
- Jupiter Neurosciences Inc trading resumes
- Jupiter Neurosciences Inc trading halted, volatility trading pause
- Jupiter Neurosciences announces focus on NLRP3 pathway in JOTROL trials
- Jupiter Neurosciences jumps 19%, halts, after Greenridge starts at Buy